Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial

253 Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial

(2012) H. Rugo et al.   EUROPEAN JOURNAL OF CANCER

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer

(2011) Y. Wu et al.   ANNALS OF ONCOLOGY

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

(2011) Francesco Nuzzo et al.   BMC CANCER

Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2– Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials

(2011) Maria Rosa Strada et al.   Clinical Breast Cancer

Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer

(2011) Helene Svensson et al.   MEDICAL ONCOLOGY

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

(2010) Helene Svensson et al.   BREAST CANCER RESEARCH AND TREATMENT

Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer

(2010) Karis K.F. Cheng et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Decrease in Depression Symptoms Is Associated With Longer Survival in Patients With Metastatic Breast Cancer: A Secondary Analysis

(2010) Janine Giese-Davis et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality of Life in Hormone Receptor-Positive HER-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib

(2010) B. Sherrill et al.   ONCOLOGIST

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

(2010) John T. Maringwa et al.   SUPPORTIVE CARE IN CANCER

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

(2009) Xiaolei Zhou et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007

(2008) Ali Montazeri   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH